GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Price-to-Owner-Earnings

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Price-to-Owner-Earnings : 11.45 (As of Apr. 28, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Price-to-Owner-Earnings?

As of today (2024-04-28), Santen Pharmaceutical Co's share price is $9.39. Santen Pharmaceutical Co's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.82. It's Price-to-Owner-Earnings for today is 11.45.


The historical rank and industry rank for Santen Pharmaceutical Co's Price-to-Owner-Earnings or its related term are showing as below:

SNPHY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.62   Med: 20.22   Max: 652
Current: 11.42

During the past 13 years, the highest Price-to-Owner-Earnings of Santen Pharmaceutical Co was 652.00. The lowest was 10.62. And the median was 20.22.


SNPHY's Price-to-Owner-Earnings is ranked better than
84.8% of 421 companies
in the Drug Manufacturers industry
Industry Median: 27.58 vs SNPHY: 11.42

As of today (2024-04-28), Santen Pharmaceutical Co's share price is $9.39. Santen Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.53. Therefore, Santen Pharmaceutical Co's PE Ratio for today is 17.89.

As of today (2024-04-28), Santen Pharmaceutical Co's share price is $9.39. Santen Pharmaceutical Co's EPS without NRI for the trailing twelve months (TTM) ended in was $0.53. Therefore, Santen Pharmaceutical Co's PE Ratio without NRI for today is 17.89.

During the past 13 years, Santen Pharmaceutical Co's highest PE Ratio without NRI was 73.92. The lowest was 10.35. And the median was 23.97.


Santen Pharmaceutical Co Price-to-Owner-Earnings Historical Data

The historical data trend for Santen Pharmaceutical Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Price-to-Owner-Earnings Chart

Santen Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.31 18.47 - 13.13 -

Santen Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 17.21 10.59

Competitive Comparison of Santen Pharmaceutical Co's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Price-to-Owner-Earnings falls into.



Santen Pharmaceutical Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Santen Pharmaceutical Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=9.39/0.82
=11.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co  (OTCPK:SNPHY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Santen Pharmaceutical Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020